

# Stefania Conti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2381953/publications.pdf>

Version: 2024-02-01

121  
papers

3,090  
citations

159585

30  
h-index

206112

48  
g-index

121  
all docs

121  
docs citations

121  
times ranked

2272  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Monoclonal Antibody Directed against a <i>Candida albicans</i> Cell Wall Mannoprotein Exerts Three Anti- <i>C. albicans</i> Activities. <i>Infection and Immunity</i> , 2003, 71, 5273-5279.	2.2	150
2	Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. <i>Nature Biotechnology</i> , 1997, 15, 155-158.	17.5	136
3	Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. <i>Nature Biotechnology</i> , 2000, 18, 1060-1064.	17.5	125
4	Therapeutic Activity of an Engineered Synthetic Killer Antiidiotypic Antibody Fragment against Experimental Mucosal and Systemic Candidiasis. <i>Infection and Immunity</i> , 2003, 71, 6205-6212.	2.2	104
5	AFM1 in Milk: Physical, Biological, and Prophylactic Methods to Mitigate Contamination. <i>Toxins</i> , 2015, 7, 4330-4349.	3.4	97
6	Interplay between Protective and Inhibitory Antibodies Dictates the Outcome of Experimentally Disseminated Candidiasis in Recipients of a <i>Candida albicans</i> Vaccine. <i>Infection and Immunity</i> , 2002, 70, 5462-5470.	2.2	89
7	Natural and synthetic peptides with antifungal activity. <i>Future Medicinal Chemistry</i> , 2016, 8, 1413-1433.	2.3	83
8	Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature?. <i>Trends in Immunology</i> , 1997, 18, 164-169.	7.5	76
9	Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities. <i>PLoS ONE</i> , 2008, 3, e2371.	2.5	76
10	Protection of Killer Antiidiotypic Antibodies against Early Invasive Aspergillosis in a Murine Model of Allogeneic T-Cell-Depleted Bone Marrow Transplantation. <i>Infection and Immunity</i> , 2002, 70, 2375-2382.	2.2	67
11	Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes. <i>Nature Medicine</i> , 1998, 4, 705-709.	30.7	64
12	Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of <i>Candida</i> Species. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2953-2958.	3.9	58
13	From yeast killer toxins to antibiobodies and beyond. <i>FEMS Microbiology Letters</i> , 2008, 288, 1-8.	1.8	56
14	Idiotypic Vaccination: Immunoprotection Mediated by Anti-idiotypic Antibodies with Antibiotic Activity. <i>Scandinavian Journal of Immunology</i> , 1993, 37, 105-110.	2.7	53
15	A <i>Wickerhamomyces anomalus</i> Killer Strain in the Malaria Vector <i>Anopheles stephensi</i> . <i>PLoS ONE</i> , 2014, 9, e95988.	2.5	50
16	Antibody Complementarity-Determining Regions (CDRs): A Bridge between Adaptive and Innate Immunity. <i>PLoS ONE</i> , 2009, 4, e8187.	2.5	48
17	A synthetic peptide as a novel anticryptococcal agent. <i>Cellular Microbiology</i> , 2004, 6, 953-961.	2.1	45
18	Mycobactericidal Activity of Human Natural, Monoclonal, and Recombinant Yeast Killer Toxin-like Antibodies. <i>Journal of Infectious Diseases</i> , 1998, 177, 807-811.	4.0	44

#	ARTICLE	IF	CITATIONS
19	From <i>Pichia anomala</i> killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy. <i>Antonie Van Leeuwenhoek</i> , 2011, 99, 35-41.	1.7	43
20	Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 956-958.	3.0	41
21	Production of an Engineered Killer Peptide in <i>Nicotiana benthamiana</i> by Using a Potato virus X Expression System. <i>Applied and Environmental Microbiology</i> , 2005, 71, 6360-6367.	3.1	41
22	Peptides of the Constant Region of Antibodies Display Fungicidal Activity. <i>PLoS ONE</i> , 2012, 7, e34105.	2.5	41
23	<i>Hansenula anomala</i> killer toxin induces secretion and severe acute injury in the rat intestine. <i>Gastroenterology</i> , 1995, 109, 1900-1906.	1.3	40
24	Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of <i>Candida albicans</i> . <i>Journal of Immunological Methods</i> , 1990, 132, 205-209.	1.4	39
25	Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. <i>Translational Oncology</i> , 2010, 3, 204-217.	3.7	39
26	Antibodies as Crypts of Antiinfective and Antitumor Peptides. <i>Current Medicinal Chemistry</i> , 2009, 16, 2305-2323.	2.4	36
27	Biotyping of bacterial isolates using the yeast killer system. <i>European Journal of Epidemiology</i> , 1989, 5, 303-310.	5.7	33
28	Studies on the epidemiology of <i>Aspergillus fumigatus</i> infections in a university hospital. <i>European Journal of Epidemiology</i> , 1989, 5, 8-14.	5.7	33
29	Interfaces of the Yeast Killer Phenomenon. <i>Critical Reviews in Microbiology</i> , 1991, 18, 47-87.	6.1	33
30	New immunotherapeutic strategies to control vaginal candidiasis. <i>Trends in Molecular Medicine</i> , 2002, 8, 121-126.	6.7	33
31	Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. <i>FEMS Yeast Research</i> , 2004, 5, 11-18.	2.3	33
32	Protective Antifungal Yeast Killer Toxin-Like Antibodies. <i>Current Molecular Medicine</i> , 2005, 5, 443-452.	1.3	33
33	Heat-Shock Mannoproteins as Targets of Secretory IgA in <i>Candida albicans</i> . <i>Journal of Infectious Diseases</i> , 1994, 169, 1401-1405.	4.0	30
34	<i>Mycobacterium parmense</i> sp. nov.. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2004, 54, 1123-1127.	1.7	30
35	Activity of an engineered synthetic killer peptide on <i>Leishmania major</i> and <i>Leishmania infantum</i> promastigotes. <i>Experimental Parasitology</i> , 2006, 113, 186-192.	1.2	30
36	In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 891-898.	3.0	30

#	ARTICLE	IF	CITATIONS
37	Inhibition by Yeast Killer Toxin-like Antibodies of Oral Streptococci Adhesion to Tooth Surfaces in an Ex Vivo Model. <i>Molecular Medicine</i> , 2002, 8, 313-317.	4.4	29
38	In Vitro Leishmanicidal Activity of a Monoclonal Antibody mimicking a Yeast Killer Toxin. <i>Journal of Eukaryotic Microbiology</i> , 2002, 49, 319-323.	1.7	29
39	Therapeutic Activity of an Anti-Idiotypic Antibody-Derived Killer Peptide against Influenza A Virus Experimental Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4331-4337.	3.2	28
40	Reversible Self-Assembly: A Key Feature for a New Class of Autodelivering Therapeutic Peptides. <i>Molecular Pharmaceutics</i> , 2009, 6, 1036-1039.	4.6	27
41	Antibody Peptide Based Antifungal Immunotherapy. <i>Frontiers in Microbiology</i> , 2012, 3, 190.	3.5	26
42	Inhibitory Effect of Human Natural Yeast Killer Toxin-like Candidacidal Antibodies on <i>Pneumocystis carinii</i> . <i>Molecular Medicine</i> , 1997, 3, 544-552.	4.4	25
43	Engineered Killer Mimotopes: New Synthetic Peptides for Antimicrobial Therapy. <i>Current Medicinal Chemistry</i> , 2004, 11, 1793-1800.	2.4	25
44	In vitro antifungal susceptibility to six antifungal agents of 229 <i>Candida</i> isolates from patients with diabetes mellitus. <i>Oral Microbiology and Immunology</i> , 2006, 21, 177-182.	2.8	25
45	The synthetic killer peptide KP impairs <i>Candida albicans</i> biofilm in vitro. <i>PLoS ONE</i> , 2017, 12, e0181278.	2.5	25
46	Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs. <i>Future Medicinal Chemistry</i> , 2011, 3, 1209-1231.	2.3	24
47	Novel Activity of a Synthetic Decapeptide Against <i>Toxoplasma gondii</i> Tachyzoites. <i>Frontiers in Microbiology</i> , 2018, 9, 753.	3.5	23
48	Killer factor interference in mixed opportunistic yeast cultures. <i>Mycopathologia</i> , 1996, 135, 1-8.	3.1	22
49	A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication. <i>Aids</i> , 2006, 20, 975-980.	2.2	22
50	Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. <i>Journal of Leukocyte Biology</i> , 2006, 79, 40-45.	3.3	22
51	Structural and functional characterization of the porcine proline-rich antifungal peptide SP $\beta$ isolated from salivary gland granules. <i>Journal of Peptide Science</i> , 2008, 14, 251-260.	1.4	22
52	Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. <i>Intervirology</i> , 2018, 61, 166-173.	2.8	21
53	Vaccination of Lactating Dairy Cows for the Prevention of Aflatoxin B1 Carry Over in Milk. <i>PLoS ONE</i> , 2011, 6, e26777.	2.5	21
54	Reactivity of <i>Candida albicans</i> Germ Tubes with Salivary Secretory IgA. <i>Journal of Dental Research</i> , 1996, 75, 1979-1985.	5.2	20

#	ARTICLE	IF	CITATIONS
55	Antimicrobial peptides with antiprotozoal activity: current state and future perspectives. <i>Future Medicinal Chemistry</i> , 2018, 10, 2569-2572.	2.3	19
56	Inhibitory effect of a yeast killer toxin to the in vitro <i>Pneumocystis carinii</i> attachment. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1993, 5, 102-106.	0.2	18
57	Protective Immunization against Group B Meningococci Using Anti-Idiotypic Mimics of the Capsular Polysaccharide. <i>Journal of Immunology</i> , 2004, 172, 2461-2468.	0.8	18
58	Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci. <i>Journal of Experimental Medicine</i> , 2006, 203, 111-118.	8.5	18
59	Antibody Constant Region Peptides Can Display Immunomodulatory Activity through Activation of the Dectin-1 Signalling Pathway. <i>PLoS ONE</i> , 2012, 7, e43972.	2.5	17
60	Effect of different wavelengths and dyes on <i>Candida albicans</i> : In vivo study using <i>Galleria mellonella</i> as an experimental model. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 18, 34-38.	2.6	17
61	In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of <i>Candida</i> spp. differently susceptible to conventional antifungals. <i>Oral Microbiology and Immunology</i> , 2005, 20, 226-232.	2.8	16
62	Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6920.	3.0	16
63	Biotyping of pathogenic fungi by the killer system and with monoclonal antibodies. <i>Mycopathologia</i> , 1989, 107, 17-23.	3.1	15
64	Discovering a new class of antifungal agents that selectively inhibits microbial carbonic anhydrases. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 1537-1544.	5.2	15
65	Serological study of yeast killer toxins by monoclonal antibodies. <i>Mycopathologia</i> , 1989, 108, 211-215.	3.1	14
66	Killer toxin secretion through the cell wall of the yeast <i>Pichia anomala</i> . <i>Mycopathologia</i> , 1994, 126, 173-177.	3.1	14
67	Biotechnological Approaches to the Production of Idiotypic Vaccines and Antiidiotypic Antibiotics. <i>Current Pharmaceutical Biotechnology</i> , 2003, 4, 91-97.	1.6	14
68	Structural and functional studies on a proline-rich peptide isolated from swine saliva endowed with antifungal activity towards <i>Cryptococcus neoformans</i> . <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 1066-1074.	2.6	14
69	In vitro and in vivo activity of a killer peptide against <i>Malassezia pachydermatis</i> causing otitis in dogs. <i>Medical Mycology</i> , 2014, 52, 350-355.	0.7	14
70	A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents. <i>Scientific Reports</i> , 2016, 6, 35018.	3.3	14
71	Ultrastructural immunodetection of a <i>Pichia anomala</i> killer toxin: a preliminary study. <i>Biology of the Cell</i> , 1992, 75, 19-23.	2.0	13
72	In vitro bactericidal effect of Nd:YAG laser on <i>Actinomyces israelii</i> . <i>Lasers in Medical Science</i> , 2013, 28, 1131-1135.	2.1	13

#	ARTICLE	IF	CITATIONS
73	Antimicrobial Photodynamic Therapy Protocols on Streptococcus mutans with Different Combinations of Wavelengths and Photosensitizing Dyes. Bioengineering, 2019, 6, 42.	3.5	13
74	Vaccination of Heifers with Anaflatoxin Improves the Reduction of Aflatoxin B1 Carry Over in Milk of Lactating Dairy Cows. PLoS ONE, 2014, 9, e94440.	2.5	13
75	Yeast Killer Toxin-Like Candidacidal Ab6 Antibodies Elicited through the Manipulation of the Idiotypic Cascade. PLoS ONE, 2014, 9, e105727.	2.5	13
76	XIX. A transphyletic anti-infectious control strategy based on the killer phenomenon. FEMS Immunology and Medical Microbiology, 1998, 22, 151-161.	2.7	12
77	Mitochondrial alterations and autofluorescent conversion of Candida albicans induced by histatins. Microscopy Research and Technique, 2005, 66, 219-228.	2.2	11
78	Dissecting the Structure-Function Relationship of a Fungicidal Peptide Derived from the Constant Region of Human Immunoglobulins. Antimicrobial Agents and Chemotherapy, 2016, 60, 2435-2442.	3.2	11
79	Fungicidal activity of peptides encoded by immunoglobulin genes. Scientific Reports, 2017, 7, 10896.	3.3	11
80	Production of yeast killer toxin in experimentally infected animals. Mycopathologia, 1990, 110, 169-175.	3.1	10
81	In Vitro Activity (MIC and MFC) of Voriconazole, Amphotericin B, and Itraconazole Against 192 Filamentous Fungi: The GISIA-2 Study. Journal of Chemotherapy, 2007, 19, 508-513.	1.5	10
82	In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs. Journal of Oral Pathology and Medicine, 2007, 36, 468-471.	2.7	10
83	Candidacidal Activity of a Novel Killer Toxin from Wickerhamomyces anomalus against Fluconazole-Susceptible and -Resistant Strains. Toxins, 2018, 10, 68.	3.4	9
84	New strategies for treatment of Candida vaginal infections. Revista Iberoamericana De Micologia, 2002, 19, 144-8.	0.9	9
85	Antimicrobial activity of poultry bone and meat trimmings hydrolyzates in low-sodium turkey food. Food and Function, 2014, 5, 220-228.	4.6	8
86	Antibodies as a source of anti-infective peptides: an update. Future Microbiology, 2015, 10, 1163-1175.	2.0	8
87	The activity of a mammalian proline-rich peptide against Gram-negative bacteria, including drug-resistant strains, relies on a nonmembranolytic mode of action. Infection and Drug Resistance, 2018, Volume 11, 969-979.	2.7	8
88	Antimicrobial effect on Candida albicans biofilm by application of different wavelengths and dyes and the synthetic killer decapeptide KP. Laser Therapy, 2019, 28, 180-186.	0.3	8
89	Activity of Two Antimicrobial Peptides against Enterococcus faecalis in a Model of Biofilm-Mediated Endodontic Infection. Antibiotics, 2021, 10, 1220.	3.7	8
90	Inhibition by yeast killer toxin-like antibodies of oral Streptococci adhesion to tooth surfaces in an ex vivo model. Molecular Medicine, 2002, 8, 313-7.	4.4	8

#	ARTICLE	IF	CITATIONS
91	Screening of a <i>Saccharomyces cerevisiae</i> nonessential gene deletion collection for altered susceptibility to a killer peptide. <i>New Microbiologica</i> , 2008, 31, 143-5.	0.1	8
92	Differential toxinogenesis in the genus <i>Pichia</i> detected by an anti-yeast killer toxin monoclonal antibody. <i>Antonie Van Leeuwenhoek</i> , 1991, 59, 139-145.	1.7	8
93	Metabolic Plasticity of <i>Candida albicans</i> in Response to Different Environmental Conditions. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 723.	3.5	8
94	Diagnostic potential of IgA coated <i>Candida</i> cells in mucous membrane candidiasis. <i>Mycopathologia</i> , 1991, 116, 105-112.	3.1	7
95	Anaerobic yeast killer systems. <i>European Journal of Epidemiology</i> , 1992, 8, 471-476.	5.7	7
96	<i>Candida albicans</i> stress mannoproteins expression in superficial and systemic candidiasis. <i>Mycopathologia</i> , 1996, 133, 89-94.	3.1	7
97	Peptides from the inside of the antibodies are active against infectious agents and tumours. <i>Journal of Peptide Science</i> , 2015, 21, 370-378.	1.4	7
98	A Peptide Found in Human Serum, Derived from the C-Terminus of Albumin, Shows Antifungal Activity In Vitro and In Vivo. <i>Microorganisms</i> , 2020, 8, 1627.	3.6	7
99	In Vitro and In Vivo Anti- <i>Candida</i> Activity and Structural Analysis of Killer Peptide (KP)-Derivatives. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 129.	3.5	7
100	In Vitro Decrease of Rat-derived <i>Pneumocystis carinii</i> Attachment Induced by Human Natural Yeast Killer Toxin-like Antiidiotypic <i>Candidacidal</i> Antibodies. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 27S-27S.	1.7	6
101	Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens. <i>Anti-Infective Agents in Medicinal Chemistry</i> , 2007, 6, 263-272.	0.6	6
102	Antibodies as an Unlimited Source of Anti-Infective, Anti-Tumour and Immunomodulatory Peptides. <i>Science Progress</i> , 2014, 97, 215-233.	1.9	6
103	Dissection of the Structural Features of a Fungicidal Antibody-Derived Peptide. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3792.	4.1	6
104	<i>Wickerhamomyces</i> Yeast Killer Toxins™ Medical Applications. <i>Toxins</i> , 2021, 13, 655.	3.4	6
105	Therapeutic Effect of an Antibody-Derived Peptide in a <i>Galleria mellonella</i> Model of Systemic Candidiasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10904.	4.1	6
106	Engineered Commensal Bacteria as Delivery Systems of Anti-infective Mucosal Protectants. <i>Biotechnology and Genetic Engineering Reviews</i> , 2002, 19, 139-158.	6.2	5
107	Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi. <i>Microorganisms</i> , 2021, 9, 143.	3.6	5
108	In Silico Predicted Antifungal Peptides: In Vitro and In Vivo Anti- <i>Candida</i> Activity. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 439.	3.5	5

#	ARTICLE	IF	CITATIONS
109	Antimicrobial Peptide L18R Displays a Modulating Action against Inter-Kingdom Biofilms in the Lubbock Chronic Wound Biofilm Model. <i>Microorganisms</i> , 2021, 9, 1779.	3.6	5
110	Personalized antifungal susceptibility testing. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 43, 333-338.	3.0	4
111	Biotyping of <i>Candida albicans</i> and Other Fungi by Yeast Killer Toxins Sensitivity. <i>Methods in Molecular Biology</i> , 2009, 499, 97-115.	0.9	3
112	Factors influencing the expression in vitro of <i>Candida albicans</i> stress mannoproteins reactive with salivary secretory IgA. <i>Mycopathologia</i> , 1998, 141, 1-6.	3.1	2
113	Photodynamic therapy: a synergy between light and colors. <i>Proceedings of SPIE</i> , 2015, , .	0.8	2
114	Genomic studies on killer yeasts belonging to the genus <i>Pichia</i> . <i>Antonie Van Leeuwenhoek</i> , 1992, 62, 215-223.	1.7	1
115	Killer antibodies in fungal infections. <i>Research in Immunology</i> , 1998, 149, 334-343.	0.9	1
116	XIX. A transphyletic anti-infectious control strategy based on the killer phenomenon. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 22, 151-161.	2.7	1
117	Activity of a killer peptide on the growth and ultrastructure of leishmaniae. <i>Journal of Eukaryotic Microbiology</i> , 2005, 52, 38S-43S.	1.7	0
118	First Italian report of onychomycosis caused by <i>Onychocola canadensis</i> . <i>Medical Mycology</i> , 2003, 41, 447-450.	0.7	0
119	Yeast Killer Toxins Technology Transfer. , 2009, , 275-290.		0
120	Effect of <i>Pichia anomala</i> killer toxin on <i>Candida albicans</i> . <i>Medical Mycology</i> , 1998, 36, 199-204.	0.7	0
121	Idiotypic Antifungal Vaccination: Immunoprotection by Antiidiotypic Antibiotic Antibodies. <i>Methods in Molecular Biology</i> , 2017, 1625, 97-112.	0.9	0